Radiotracers for Bone Marrow Infection Imaging
- PMID: 34070537
- PMCID: PMC8198735
- DOI: 10.3390/molecules26113159
Radiotracers for Bone Marrow Infection Imaging
Abstract
Introduction: Radiotracers are widely used in medical imaging, using techniques of gamma-camera imaging (scintigraphy and SPECT) or positron emission tomography (PET). In bone marrow infection, there is no single routine test available that can detect infection with sufficiently high diagnostic accuracy. Here, we review radiotracers used for imaging of bone marrow infection, also known as osteomyelitis, with a focus on why these molecules are relevant for the task, based on their physiological uptake mechanisms. The review comprises [67Ga]Ga-citrate, radiolabelled leukocytes, radiolabelled nanocolloids (bone marrow) and radiolabelled phosphonates (bone structure), and [18F]FDG as established radiotracers for bone marrow infection imaging. Tracers that are under development or testing for this purpose include [68Ga]Ga-citrate, [18F]FDG, [18F]FDS and other non-glucose sugar analogues, [15O]water, [11C]methionine, [11C]donepezil, [99mTc]Tc-IL-8, [68Ga]Ga-Siglec-9, phage-display selected peptides, and the antimicrobial peptide [99mTc]Tc-UBI29-41 or [68Ga]Ga-NOTA-UBI29-41.
Conclusion: Molecular radiotracers allow studies of physiological processes such as infection. None of the reviewed molecules are ideal for the imaging of infections, whether bone marrow or otherwise, but each can give information about a separate aspect such as physiology or biochemistry. Knowledge of uptake mechanisms, pitfalls, and challenges is useful in both the use and development of medically relevant radioactive tracers.
Keywords: FDG; FDS; Ga-citrate; IL-8; PET; SPECT; Siglec-9; UBI; methionine; osteomyelitis; radionuclides; ubiquicidin.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003
-
Preclinical evaluation of 68Ga-labeled 1,4,7-triazacyclononane-1,4,7-triacetic acid-ubiquicidin as a radioligand for PET infection imaging.J Nucl Med. 2014 Feb;55(2):308-14. doi: 10.2967/jnumed.113.128397. Epub 2014 Jan 16. J Nucl Med. 2014. PMID: 24434293
-
Nuclear medicine imaging of bone infections.Clin Radiol. 2016 Jul;71(7):632-46. doi: 10.1016/j.crad.2016.01.003. Epub 2016 Feb 17. Clin Radiol. 2016. PMID: 26897336 Review.
-
(68)Ga-radiopharmaceuticals for PET imaging of infection and inflammation.Recent Results Cancer Res. 2013;194:189-219. doi: 10.1007/978-3-642-27994-2_11. Recent Results Cancer Res. 2013. PMID: 22918761 Review.
-
Peptide synthesis, characterization and ⁶⁸Ga-radiolabeling of NOTA-conjugated ubiquicidin fragments for prospective infection imaging with PET/CT.Nucl Med Biol. 2014 May-Jun;41(5):390-400. doi: 10.1016/j.nucmedbio.2014.02.001. Epub 2014 Feb 13. Nucl Med Biol. 2014. PMID: 24630816
Cited by
-
Radiosynthesis and Preclinical Evaluation of [99mTc]Tc-Tigecycline Radiopharmaceutical to Diagnose Bacterial Infections.Pharmaceuticals (Basel). 2024 Sep 27;17(10):1283. doi: 10.3390/ph17101283. Pharmaceuticals (Basel). 2024. PMID: 39458924 Free PMC article.
-
Application of Nuclear Medicine Techniques in Musculoskeletal Infection: Current Trends and Future Prospects.J Clin Med. 2024 Feb 13;13(4):1058. doi: 10.3390/jcm13041058. J Clin Med. 2024. PMID: 38398371 Free PMC article. Review.
-
Alternatives for the Detection and Diagnosis of Osteoarticular Infections: An Exploratory Review.Cureus. 2024 Jul 3;16(7):e63743. doi: 10.7759/cureus.63743. eCollection 2024 Jul. Cureus. 2024. PMID: 39099945 Free PMC article. Review.
-
Preclinical Testing of Radiopharmaceuticals for the Detection and Characterization of Osteomyelitis: Experiences from a Porcine Model.Molecules. 2021 Jul 12;26(14):4221. doi: 10.3390/molecules26144221. Molecules. 2021. PMID: 34299496 Free PMC article. Review.
-
Zinc-Doped Iron Oxide Nanoparticles as a Proton-Activatable Agent for Dose Range Verification in Proton Therapy.Molecules. 2023 Sep 29;28(19):6874. doi: 10.3390/molecules28196874. Molecules. 2023. PMID: 37836718 Free PMC article.
References
-
- Johansen L.K., Koch J., Kirketerp-Møller K., Wamsler O.J., Nielsen O.L., Leifsson P.S., Frees D., Aalbæk B., Jensen H.E. Therapy of haematogenous osteomyelitis—A comparative study in a porcine model and angolan children. In Vivo. 2013;27:305–312. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials